Quarterly Revenue and Profitability
Q2 revenue of $5.4 billion, EBITDA of $826 million and EBIT of $603 million; adjusted EPS of $0.86 for the quarter (post one-for-five reverse split). Adjusted EPS was up 7% in Q2 and 14% for the first half versus prior year.
Synergy Acceleration and Targets
Synergies accelerated to $55 million in Q2 and $93 million in the first half. Management is confident in delivering at least $260 million of synergies in fiscal 2026 and a total of $650 million through fiscal 2028; procurement target of $325 million by 2028. G&A and procurement synergies in Q2 were roughly evenly split.
Reaffirmed Financial Guidance
Company reaffirmed full-year guidance with expected adjusted EPS growth of 12%–17% year-over-year and free cash flow guidance of $1.8 billion to $1.9 billion for fiscal 2026. (Note: presenters referenced EPS ranges reflecting the reverse split: $4.20–$4.50 and $4.00–$4.15.)
Core Portfolio Strength
Defined $20 billion core portfolio outperforms the total company across key metrics: core volumes were ~1.5% lower YoY, ~100 basis points better than the total combined portfolio; adjusted EBIT dollars in the core were up approximately 7% (driven by synergies) and adjusted EBIT margins of ~12%.
Segment Performance — Rigid and Flexible
Flexible Packaging sales increased ~23% on a constant currency basis (driven by Berry acquisition); comparable flexible volumes down ~2% with adjusted EBIT up ~22% CC to $402 million and comparable adjusted EBIT up ~1% CC. Rigid Packaging had comparable volumes flat (ex non-core) and adjusted EBIT of $228 million; comparable adjusted EBIT up 15% (ex non-core) with margin improvement ~200 basis points to 12%.
Cash Flow, Leverage and Capital Allocation
Q2 free cash flow of $289 million; first half cash outflow of $53 million (in line with acquisition expectations). FY26 capital spend expected $850–$900 million (H1 capex $459 million). Adjusted leverage exiting Q2 was 3.6x with an expected year-end leverage of 3.1–3.2x.
Commercial Wins and Revenue Synergies
Annualized sales revenue from wins directly linked to the Berry combination now exceeds $100 million, on track toward the three-year target of $280 million. Example wins include supporting a major pharma GLP-1 therapy with blister and rigid packaging across regions.
Shareholder Returns and Organizational Progress
Board declared a quarterly dividend of $0.65 per share (increase vs prior year). Integration progress includes >600 headcount reductions, ~20 site closures/restructures approved or announced, and early fiscal benefits (~$10 million) from debt/tax optimization.